NO20030061L - Tyrosinderivater som fosfataseinhibitorer - Google Patents

Tyrosinderivater som fosfataseinhibitorer

Info

Publication number
NO20030061L
NO20030061L NO20030061A NO20030061A NO20030061L NO 20030061 L NO20030061 L NO 20030061L NO 20030061 A NO20030061 A NO 20030061A NO 20030061 A NO20030061 A NO 20030061A NO 20030061 L NO20030061 L NO 20030061L
Authority
NO
Norway
Prior art keywords
compounds
phosphatase inhibitors
tyrosine derivatives
diabetes mellitus
type
Prior art date
Application number
NO20030061A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030061D0 (no
Inventor
Laurence E Burgess
John J Gaudino
Robert D Groneberg
Mark H Norman
Martha E Rodriguez
Xicheng David Sun
Eli M Wallace
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20030061D0 publication Critical patent/NO20030061D0/no
Publication of NO20030061L publication Critical patent/NO20030061L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Fats And Perfumes (AREA)
NO20030061A 2000-07-06 2003-01-06 Tyrosinderivater som fosfataseinhibitorer NO20030061L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21620100P 2000-07-06 2000-07-06
PCT/US2001/041271 WO2002004412A2 (fr) 2000-07-06 2001-07-05 Preparation d'inhibiteurs de phosphatase

Publications (2)

Publication Number Publication Date
NO20030061D0 NO20030061D0 (no) 2003-01-06
NO20030061L true NO20030061L (no) 2003-03-05

Family

ID=22806135

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030061A NO20030061L (no) 2000-07-06 2003-01-06 Tyrosinderivater som fosfataseinhibitorer

Country Status (15)

Country Link
US (1) US6586467B2 (fr)
EP (1) EP1301474B1 (fr)
JP (1) JP2004502754A (fr)
KR (1) KR100788510B1 (fr)
AT (1) ATE407923T1 (fr)
AU (2) AU7818801A (fr)
BR (1) BR0112216A (fr)
CA (1) CA2416220C (fr)
DE (1) DE60135752D1 (fr)
ES (1) ES2312461T3 (fr)
IL (2) IL153804A0 (fr)
MX (1) MXPA03000166A (fr)
NO (1) NO20030061L (fr)
NZ (1) NZ523483A (fr)
WO (1) WO2002004412A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020169157A1 (en) * 2000-08-29 2002-11-14 Gang Liu Selective protein tyrosine phosphatatase inhibitors
US20040191926A1 (en) * 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
WO2004071448A2 (fr) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Derives d'azole substitues comme agents therapeutiques
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
CN1922151A (zh) * 2004-02-12 2007-02-28 特兰斯泰克制药公司 取代的吡咯衍生物、组合物和使用方法
WO2005114197A2 (fr) * 2004-04-15 2005-12-01 Albert Einstein College Of Medicine Of Yeshiva University Sondes à activité pour les protéines tyrosine phosphatase
AU2007211319B9 (en) 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors
EP2601946A1 (fr) * 2011-12-06 2013-06-12 Pécsi Tudomànyegyetem Traitement et prévention des maladies liées au stress oxydatif
WO2013142010A1 (fr) * 2012-03-20 2013-09-26 Temple University - Of The Commonwealth System Of Higher Education Dérivés de 3-aminothieno[3,2-c]quinoline, procédés de préparation et utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707559A (en) * 1971-05-14 1972-12-26 Searle & Co N-acyl phenylalanine amides
DE69116576T2 (de) * 1991-09-05 1996-10-10 Pharno Wedropharm Gmbh Aromatische sulfonamidderivate, ihre verwendung als enzyminhibitoren und diese verbindungen enthaltende pharmazeutische zusammensetzungen
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
DE4425781A1 (de) * 1994-07-14 1996-01-18 Schering Ag Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel
DE69824433D1 (en) * 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6410585B1 (en) * 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
JPH11246511A (ja) * 1998-02-25 1999-09-14 Kanebo Ltd 硫酸エステル誘導体
US6613801B2 (en) * 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
WO2002063299A1 (fr) * 2001-02-05 2002-08-15 Graffinity Pharmaceuticals Ag Procede de criblage des faibles affinites

Also Published As

Publication number Publication date
KR100788510B1 (ko) 2007-12-24
MXPA03000166A (es) 2004-09-13
US20020040003A1 (en) 2002-04-04
DE60135752D1 (en) 2008-10-23
CA2416220C (fr) 2010-04-06
ATE407923T1 (de) 2008-09-15
IL153804A0 (en) 2003-07-31
WO2002004412A3 (fr) 2002-08-22
ES2312461T3 (es) 2009-03-01
AU2001278188B2 (en) 2007-05-17
KR20030029613A (ko) 2003-04-14
CA2416220A1 (fr) 2002-01-17
JP2004502754A (ja) 2004-01-29
WO2002004412A2 (fr) 2002-01-17
NO20030061D0 (no) 2003-01-06
US6586467B2 (en) 2003-07-01
NZ523483A (en) 2004-08-27
IL153804A (en) 2009-12-24
BR0112216A (pt) 2004-02-10
AU7818801A (en) 2002-01-21
EP1301474A2 (fr) 2003-04-16
EP1301474B1 (fr) 2008-09-10

Similar Documents

Publication Publication Date Title
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
WO2002057252A3 (fr) Inhibiteurs sulfonamides heterocycliques de la production de beta-amyloide
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
WO2004056786A3 (fr) Composes pour traiter le developpement anormal de cellules
NO20015172L (no) 1-metyl-erytromycin-derivater
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
DK1263730T3 (da) Aminderivater til behandling af apoptose
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
ES2243579T3 (es) Derivados de pirazolopirideno.
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
NO20030061D0 (no) Tyrosinderivater som fosfataseinhibitorer
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
MXPA04006041A (es) Antivirales de piridoquinoxalina.
WO2007014839A3 (fr) Inhibiteurs de la cathepsine k
WO2001081316A3 (fr) Inhibiteurs de phenyle farnesyltransferase substitues
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
WO2003057213A3 (fr) Composes derives de cyclohexano- et cycloheptapyrazole destines au traitement des maladies associees au recepteur 5-ht2c
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
PL390683A1 (pl) Zastosowanie pochodnych pirolu do wytwarzania leku
DK1353660T3 (da) Anvendelse af substituerede 6-dimethylaminomethyl-1-phenylcyclohexanforbindelser til behandling af urininkontinens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application